Stockscreener 앱 받기
8.75
1.04%
0.09
시간 외 거래:
8.85
0.10
+1.14%
전일 마감가:
$8.66
열려 있는:
$8.64
하루 거래량:
1.72M
Relative Volume:
0.82
시가총액:
$1.14B
수익:
$745.97M
순이익/손실:
$-99.21M
주가수익비율:
-11.32
EPS:
-0.7729
순현금흐름:
$-5.09M
1주 성능:
-1.24%
1개월 성능:
+13.78%
6개월 성능:
-12.50%
1년 성능:
+2.82%
1일 변동 폭
$8.51
$8.89
1주일 범위
$8.47
$9.155
52주 변동 폭
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.75 | 1.13B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-29 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
TradingKey - TradingKey
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - simplywall.st
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics Inc. (NEO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NEO PE Ratio & Valuation, Is NEO Overvalued - Intellectia AI
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO) - Stock Titan
NeoGenomics (NEO) Q1 2026 Earnings Transcript - AOL.com
NEO SEC FilingsNeogenomics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
MSN Money - MSN
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Globe and Mail
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Leerink upgrades NeoGenomics to Outperform, raises target to $25 - TipRanks
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 - marketscreener.com
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat - Investing.com UK
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat By Investing.com - Investing.com South Africa
NeoGenomics Shares Jump on Earnings and Analyst Upgrades - Yahoo Finance
Leerink upgrades Neogenomics stock rating on oncology growth outlook - Investing.com
NeoGenomics upgraded to Buy from Hold at Benchmark - TipRanks
NeoGenomics stock surges following earnings, two upgrades By Investing.com - Investing.com Nigeria
NeoGenomics stock surges following earnings, two upgrades - Investing.com
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Earnings Call Summary | NeoGenomics(NEO.US) Q1 2026 Earnings Conference - Moomoo
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth - TradingView
NeoGenomics Reports First Quarter 2026 Results - BioSpace
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
0.56%
자본화:
|
볼륨(24시간):